Chronic migraine is a burdensome disease presenting with episodic pain and several symptoms that may persist even among headache attacks. Multisensory integration is modified in migraine, as assessed by the level of the perception of sound-induced flash illusions, a simple paradigm reflecting changes in cortical excitability which reveals to be altered in migraineurs. OnabotulinumtoxinA is an effective preventive therapy for chronic migraineurs, reducing peripheral and central sensitization, and may influence cortical excitability. Patients affected by chronic migraine who started onabotulinumtoxinA preventive therapy were included. Clinical effects (headache diaries and migraine related questionnaires) were assessed at the beginning of the...
Chronic migraine causes a serious labour loss and disability in the society and increases the risk o...
Migraine is a highly disabling disease characterized by recurrent pain.Despite an intensive effort, ...
Objective: To evaluate the early response of onabotulinumtoxinA as a treatment tool in patients with...
Chronic migraine is a burdensome disease presenting with episodic pain and several symptoms that may...
Neck disability and pain are frequently encountered problems in patients with chronic migraine (CM)....
Onabotulintoxin A (BontA) is an efficacious preventive treatment for chronic migraine, though the sp...
Chronic migraine is a debilitating neurobiological disorder that affects approximately 1.4–2.2% of t...
Multisensory processing can be assessed by measuring susceptibility to crossmodal illusions such as ...
Introduction: Sound-induced flash illusions(SIFI) permit to evaluate crossmodal audio-visual percept...
Background: Onabotulinumtoxin A (OBT-A) is a treatment option for chronic migraine (CM), though the ...
Background: Chronic migraine is a common, highly disabling, underdiagnosed and undertreated entity o...
OnabotulinumtoxinA (BT-A) is one of the few drugs approved for the preventive treatment of chronic m...
Here we report the effect of Onabotulinumtoxin-A (Onabot-A) in twelve patients with chronic migraine...
Recent trials have demonstrated that onabotulinumtoxinA is a safe and effective treatment for the pr...
Abstract Background OnabotulinumtoxinA is effective in preventing chronic migraine (CM); however, th...
Chronic migraine causes a serious labour loss and disability in the society and increases the risk o...
Migraine is a highly disabling disease characterized by recurrent pain.Despite an intensive effort, ...
Objective: To evaluate the early response of onabotulinumtoxinA as a treatment tool in patients with...
Chronic migraine is a burdensome disease presenting with episodic pain and several symptoms that may...
Neck disability and pain are frequently encountered problems in patients with chronic migraine (CM)....
Onabotulintoxin A (BontA) is an efficacious preventive treatment for chronic migraine, though the sp...
Chronic migraine is a debilitating neurobiological disorder that affects approximately 1.4–2.2% of t...
Multisensory processing can be assessed by measuring susceptibility to crossmodal illusions such as ...
Introduction: Sound-induced flash illusions(SIFI) permit to evaluate crossmodal audio-visual percept...
Background: Onabotulinumtoxin A (OBT-A) is a treatment option for chronic migraine (CM), though the ...
Background: Chronic migraine is a common, highly disabling, underdiagnosed and undertreated entity o...
OnabotulinumtoxinA (BT-A) is one of the few drugs approved for the preventive treatment of chronic m...
Here we report the effect of Onabotulinumtoxin-A (Onabot-A) in twelve patients with chronic migraine...
Recent trials have demonstrated that onabotulinumtoxinA is a safe and effective treatment for the pr...
Abstract Background OnabotulinumtoxinA is effective in preventing chronic migraine (CM); however, th...
Chronic migraine causes a serious labour loss and disability in the society and increases the risk o...
Migraine is a highly disabling disease characterized by recurrent pain.Despite an intensive effort, ...
Objective: To evaluate the early response of onabotulinumtoxinA as a treatment tool in patients with...